For the quarter ending 2026-03-31, SYRE had $11,464K increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -69,005 | -62,530 | -11,183 | -81,490 |
| Depreciation and amortization | - | 0 | - | - |
| Stock-based compensation | 12,806 | 9,811 | 9,566 | 18,237 |
| Acquired in-process research and development | 0 | 0 | - | - |
| Change in fair value of derivative liability-Contingent Value Right Liability | - | 29,769 | - | - |
| Change in fair value of derivative liability-Forward Contracts | - | 0 | - | - |
| Change in fair value of cvr liability | -72,469 | - | 40,399 | 1,800 |
| Gain on sale of in-process research and development asset | 30,000 | 0 | 0 | 10,000 |
| Lease rou asset and leasehold improvement impairment loss | - | 0 | - | - |
| Loss on disposal of long-lived assets | - | 0 | - | - |
| Net accretion of discount on marketable securities | 2,059 | 2,085 | 1,350 | 4,655 |
| Interest proceeds from maturities of zero coupon u.s. treasury bills | 372 | 61 | 309 | 1,760 |
| Accounts payable | -3,212 | 1,447 | 3,745 | 3,046 |
| Deferred revenue | - | 0 | - | - |
| Development receivables | - | 0 | - | - |
| Operating lease liabilities | - | 0 | - | - |
| Amortization of operating lease assets | - | 0 | - | - |
| Accrued and other liabilities | 3,653 | 3,124 | 4,411 | -8,299 |
| Other | - | 0 | - | - |
| Related party accounts payable | 36 | -3,956 | 3,939 | -572 |
| Prepaid expenses and other assets | 233 | 2,880 | 6,155 | 3,784 |
| Net cash used in operating activities | -57,372 | -44,578 | -37,117 | -87,557 |
| Proceeds from the sale of property plant and equipment | - | 0 | - | - |
| Proceeds from maturities and sales of marketable securities | 107,748 | 94,299 | 99,191 | 178,249 |
| Cash assumed from asset acquisition of spyre | - | 0 | - | - |
| Purchases of marketable securities | 81,167 | 341,709 | 74,193 | 106,312 |
| Proceeds from sale of in-process research and development asset | 30,000 | 0 | 0 | 7,000 |
| Net cash provided by (used in) investing activities | 56,581 | -247,410 | 24,998 | 78,937 |
| Proceeds from issuance of private placement, net-Series ANon Voting Convertible Preferred Stock | - | 0 | - | - |
| Proceeds from issuance of series b non-voting convertible preferred stock in connection with private placement, net of placement and other offering costs | - | - | 0 | 0 |
| Proceeds from issuance of private placement, net-Common Stock | - | 0 | - | - |
| Proceeds from issuance of private placement, net-Series BNon Voting Convertible Preferred Stock | - | 0 | - | - |
| Payment of contingent value rights liability | - | 0 | 5,251 | 0 |
| Proceeds from issuance of common stock in connection with at-the-market offering program, net of issuance costs | 9,750 | 14,750 | 0 | - |
| Cash settlement of employee stock option award | - | - | - | 117 |
| Proceeds from issuance of common stock in connection with follow-on offering, net of issuance costs | - | 296,382 | - | - |
| Payment of deferred offering costs in connection with shelf registration | 171 | 69 | 0 | 93 |
| Proceeds from employee stock option exercises and employee stock plan purchases | 2,676 | 1,749 | 491 | 1,066 |
| Other financing cash flows | - | 0 | - | - |
| Net cash provided by financing activities | 12,255 | 312,812 | -4,643 | 856 |
| Effect of exchange rate on cash, cash equivalents, and restricted cash | - | 0 | 0 | 0 |
| Net decrease in cash and cash equivalents | 11,464 | 20,824 | -16,762 | -7,764 |
| Beginning of period | 20,824 | - | 89,423 | - |
| End of period | 32,288 | - | 64,897 | - |
Spyre Therapeutics, Inc. (SYRE)
Spyre Therapeutics, Inc. (SYRE)